Database : MEDLINE
Search on : Vasculitis [Words]
References found : 32464 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 3247 go to page                         

  1 / 32464 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 25269877
[Au] Autor:Holl-Ulrich K
[Ad] Address:Konsultations- und Referenzzentrum für Vaskulitisdiagnostik, Institut für Pathologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland, konstanze.holl-ulrich@uksh.de.
[Ti] Title:Vaskulitis : Neue Nomenklatur der Chapel-Hill-Konsensuskonferenz 2012. [Vasculitis : New nomenclature of the Chapel Hill consensus conference 2012].
[So] Source:Z Rheumatol;73(9):823-35, 2014 Nov.
[Is] ISSN:1435-1250
[Cp] Country of publication:Germany
[La] Language:ger
[Ab] Abstract:Within the last years, many advances have been made in the understanding of the etiopathology of vasculitis as well as of different disease courses. The revised 2012 Chapel Hill consensus conference (CHCC) nomenclature reflects current knowledge on the etiopathology in addition to the descriptive principles of vessel size and types of inflammation. The anti-neutrophil cytoplasmic antibody (ANCA)-associated forms of vasculitis have been separated as a group, as opposed to immune complex small vessel vasculitis. When consensus was achieved eponyms have been replaced by systematic names, such as granulomatosis with polyangiitis (Wegener's granulomatosis) or eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Moreover, clinically important but less well-known types of vasculitis have now been included in the CHCC nomenclature. This article presents the changes and summarizes the results of important new articles on the clinical picture and morphology of vasculitis.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1411
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1007/s00393-014-1477-x

  2 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25372516
[Au] Autor:Saati S; Sadda SR
[Ad] Address:*Department of Ophthalmology, University of Southern California, Los Angeles, California; and †Doheny Eye Institute, University of California, Los Angeles, California.
[Ti] Title:Seronegative granulomatous polyangiitis with central retinal artery occlusion as the initial manifestation.
[So] Source:Retin Cases Brief Rep;8(4):236-9, 2014.
[Is] ISSN:1937-1578
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: To report a case of central retinal artery occlusion in a patient with autopsy-verified granulomatous polyangiitis (GP) with negative cytoplasmic antineutrophil cytoplasmic antibody. METHODS: Case report. RESULTS: A 61-year-old Hispanic man with history of tuberculosis was admitted to the hospital with worsening dyspnea. Two weeks later, he experienced sudden vision loss due to central retinal artery occlusion in his right eye. A CT of the lung revealed multiple opacities. He developed renal failure during his hospital stay. A serum cytoplasmic antineutrophil cytoplasmic antibody test was negative. Pulmonary biopsy disclosed chronic inflammation with no evidence of granuloma formation or vasculitis. He died of acute respiratory distress due to bilateral deep vein thrombosis of his lower extremities. Autopsy revealed GP. CONCLUSION: Granulomatous polyangiitis is a multisystem vasculitic disorder. Central retinal artery occlusion as the presenting manifestation of GP is very uncommon. This report demonstrates the difficulty of diagnosing GP, particularly when initial diagnostic assays (including both serology and biopsy) were negative for GP.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1411
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1097/ICB.0000000000000109

  3 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25372208
[Au] Autor:Ch'ng SW; Brent A; Banerjee S
[Ad] Address:Department of Ophthalmology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom.
[Ti] Title:Cytomegalovirus retinitis: an unusual presentation as vitreous hemorrhage.
[So] Source:Retin Cases Brief Rep;8(1):50-1, 2014.
[Is] ISSN:1937-1578
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: The purpose of this report is to describe an unusual presentation of vitreous hemorrhage (VH) in a patient with an immunosuppressive condition. METHODS: Retrospective case report. RESULTS: A 72-year-old woman with known T-cell prolymphocytic leukemia treated with a course of alemtuzumab presented to our department with a VH in her left eye after a fall. An initial diagnosis of hemorrhagic posterior vitreous detachment was made. However, as the VH was resolving, she was found to have underlying vitritis, occlusive vasculitis, and a pale optic nerve head. Vitreous biopsy confirmed cytomegalovirus retinitis. Despite treatment with intravenous foscarnet and oral valganciclovir, her vision continued to remain poor because of the severe damage from the retinal vasculitis and residual VH. CONCLUSION: As indications for immunosuppression increase, the incidence of cytomegalovirus retinitis in non-HIV-immunosuppressed patients is expected to rise. Therefore, in this subgroup of patients, we should be aware of any underlying retinitis especially in cases with an unusual presentation of VH.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1411
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1097/ICB.0000000000000002

  4 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25374639
[Au] Autor:Chebbi W; Zantour B
[Ad] Address:Service de Médecine Interne, CHU Taher Sfar Mahdia, 5100 Mahdia, Tunisie.
[Ti] Title:Vascularite cutanée paranéoplasique révélant un lymphome non hodgkinien. [Paraneoplastic cutaneous vasculitis revealing non-Hodgkin's lymphoma].
[So] Source:Pan Afr Med J;17:134, 2014.
[Is] ISSN:1937-8688
[Cp] Country of publication:Uganda
[La] Language:fre
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1411
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.11604/pamj.2014.17.134.3994

  5 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25372093
[Au] Autor:Jayne D
[Ad] Address:From the University of Cambridge, Cambridge, United Kingdom.
[Ti] Title:Extending the indications for rituximab in ANCA-associated vasculitis.
[So] Source:N Engl J Med;371(19):1839-40, 2014 Nov 6.
[Is] ISSN:1533-4406
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:COMMENT; EDITORIAL
[Em] Entry month:1411
[Js] Journal subset:AIM; IM
[St] Status:In-Process
[do] DOI:10.1056/NEJMe1410394

  6 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Clinical Trials Registry
Full text

[PMID]: 25372085
[Au] Autor:Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L; French Vasculitis Study Group
[Ad] Address:From the Département de Médecine Interne, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares (L.G., C.P., P.C., X.P., A.M., L.M.), Unité de Néphrologie, Hôpital Européen Georges-Pompidou, Université Paris Descartes (A.K.), Hôpital Bichat, Université Paris Diderot, Service de Néphrologie, INSERM Unité 699, Département Hospitalo-Universitaire FIRE (E.D.) and Département de Médecine Interne (T.P.), and Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Université Paris Descartes, INSERM Unité 738 (P.R.), Assistance Publique-Hôpitaux de Paris, Paris, Service de Pneumologie, Centre de Référence pour Maladies Pulmonaires Rares, Hôpital Universitaire Louis Pradel (C.K.), and Service de Médecine Interne, Hôpital Edouard Herriot (J.N.), Lyon, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont-Ferrand (O.A.), Service de Médecine Interne, Hôpitaux privés de Metz, Metz (F.M.), Département de Médecine Interne, Hôpitaux Universitaires de Rennes, Hôpital Sud, Université Rennes I, IGDR-UMR 6290, Rennes (O.D.), Service de Médecine Interne et Néphrologie, Hôpital Général Henri Duffaut, Avignon (P. Gobert), Département de Néphrologie and Département de Médecine Interne, Centre Hospitalier de Valenciennes, Valenciennes (T.Q.), Service de Médecine Interne, Centre Hospitalier Général de Niort, Niort (C.B.-D.), Département de Médecine Interne, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes (P. Godmer), Service de Néphrologie, Dialyse et Transplantation, Centre Hospitalier Universitaire de Grenoble, Grenoble (P.-L.C.), Service de Médecine Interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, Université Lille Nord de France, Centre Hospitalier Universitaire de Lille, Lille (P.-Y.H.), Service de Médecine Interne, Centre de Référence Labellisé pour la Prise en Charge des C
[Ti] Title:Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
[So] Source:N Engl J Med;371(19):1771-80, 2014 Nov 6.
[Is] ISSN:1533-4406
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission. METHODS: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis, or renal-limited ANCA-associated vasculitis in complete remission after a cyclophosphamide-glucocorticoid regimen were randomly assigned to receive either 500 mg of rituximab on days 0 and 14 and at months 6, 12, and 18 after study entry or daily azathioprine until month 22. The primary end point at month 28 was the rate of major relapse (the reappearance of disease activity or worsening, with a Birmingham Vasculitis Activity Score >0, and involvement of one or more major organs, disease-related life-threatening events, or both). RESULTS: The 115 enrolled patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis) received azathioprine (58 patients) or rituximab (57 patients). At month 28, major relapse had occurred in 17 patients in the azathioprine group (29%) and in 3 patients in the rituximab group (5%) (hazard ratio for relapse, 6.61; 95% confidence interval, 1.56 to 27.96; P=0.002). The frequencies of severe adverse events were similar in the two groups. Twenty-five patients in each group (P=0.92) had severe adverse events; there were 44 events in the azathioprine group and 45 in the rituximab group. Eight patients in the azathioprine group and 11 in the rituximab group had severe infections, and cancer developed in 2 patients in the azathioprine group and 1 in the rituximab group. Two patients in the azathioprine group died (1 from sepsis and 1 from pancreatic cancer). CONCLUSIONS: More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine. (Funded by the French Ministry of Health; MAINRITSAN ClinicalTrials.gov number, NCT00748644; EudraCT number, 2008-002846-51.).
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1411
[Js] Journal subset:AIM; IM
[Cl] Clinical Trial:ClinicalTrial
[St] Status:In-Process
[do] DOI:10.1056/NEJMoa1404231

  7 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25077899
[Au] Autor:Kapoor E; Cartin-Ceba R; Specks U; Leavitt J; Erickson B; Erickson D
[Ad] Address:Divisions of General Internal Medicine (E.K.), Pulmonary and Critical Care Medicine (R.C.-C., U.S.) Ophthalmology (J.L.), Radiology (B.E.), and Endocrinology (D.E.), Mayo Clinic, Rochester, Minnesota 55905.
[Ti] Title:Pituitary dysfunction in granulomatosis with polyangiitis: the mayo clinic experience.
[So] Source:J Clin Endocrinol Metab;99(11):3988-94, 2014 Nov.
[Is] ISSN:1945-7197
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:CONTEXT: Pituitary involvement in granulomatosis with polyangiitis (GPA) has been described in case reports. The aim of this study was to describe the clinical presentation and outcomes of pituitary disease in patients with GPA evaluated at a tertiary referral center. SETTING: A retrospective review of patients with GPA-related pituitary disease seen at the Mayo Clinic in Rochester, Minnesota. PATIENTS: A total of 637 patients with antineutrophil cytoplasmic antibodies-associated vasculitis were followed at our institution from 1996 through 2011. Eight patients (1.3%) with clinically confirmed pituitary involvement formed the basis of this study. INTERVENTIONS: None. MEASUREMENTS: Pituitary function was assessed with hormonal testing, including TSH, free T4, cortisol, ACTH, prolactin, FSH, LH, estradiol, T, IGF-1, and simultaneous serum and urine osmolalities. RESULTS: Secondary hypogonadism and diabetes insipidus were the predominant manifestations of pituitary disease (87.5 and 75% of patients, respectively). All patients had abnormal pituitary imaging. A sellar mass with central cystic change and peripheral enhancement was the commonest imaging finding. Pituitary disease was managed with glucocorticoids in combination with cyclophosphamide or rituximab, achieving disease remission in all but one patient. However, permanent anterior pituitary dysfunction was noted in 63% of the patients. Diabetes insipidus was more often reversible, with resolution in 66.7% of the patients. CONCLUSIONS: Pituitary involvement in GPA is rare, but it needs to be recognized to avoid unnecessary biopsies of sellar lesions encountered in the context of GPA, and to minimize the risk of irreversible pituitary function loss by prompt implementation of definitive medical therapy for the vasculitis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1411
[Js] Journal subset:AIM; IM
[St] Status:In-Data-Review
[do] DOI:10.1210/jc.2014-1962

  8 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25005330
[Au] Autor:Schmalzing M; Amann K; Tony HP
[Ad] Address:Department of Internal Medicine 2, University Hospital, Wuerzburg, Germany. schmalzing_m@ukw.de.
[Ti] Title:ANCA-positive vasculitis as a secondary autoimmune disease after autologous stem cell transplantation for systemic sclerosis: a case report.
[So] Source:Clin Exp Rheumatol;32 Suppl 86(6):222-4, 2014 Nov-Dec.
[Is] ISSN:0392-856X
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:Autologous stem cell transplantation (SCT) is increasingly used to treat autoimmune diseases (AD), in particular systemic sclerosis (SSc). Secondary autoimmune diseases are a known complication after autologous stem cell transplantations for any cause. A 43-year-old man had received an autologous stem cell transplantation for an aggressive diffuse cutaneous SSc. After mobilisation with cyclophosphamide and Granulocyte-Colony-Stimulating Factor stem cells were CD34-selected. The patient received a conditioning regimen with cyclophosphamide and Antithymocyte globulin. He had an excellent response with the modified Rodnan Skin Score decreasing from 34 to 3. One year and 4 months after SCT mild erythrocyturia without acanthocytes and proteinuria were seen for the first time on routine urinalysis. During the following year erythrocyturia increased to 131 erythrocytes /µl and protein excretion to 628 mg/g creatinine. At that time, acanthocytes of 25% finally could be detected. Due to the clearly nephritic constellation in urinalysis a renal biopsy was performed, which revealed mild global and focal-segmental sclerosing and focal-segmental proliferative glomerulonephritis without any signs of a IgA-nephropathy. The result was compatible with a renal manifestation of a small-vessel vasculitis. During the following laboratory workup ANCA of a perinuclear pattern with specificity for myeloperoxidase in high titers could be detected. Therefore the diagnosis of a p-ANCA-positive glomerulonephritis was established. As treatment, the patient received Rituximab, which turned out to be effective. We provide the first report of a patient who developed a p-ANCA-associated vasculitis after autologous stem cell transplantation for an autoimmune disease, namely systemic sclerosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1411
[Js] Journal subset:IM
[St] Status:In-Data-Review

  9 / 32464 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25374734
[Au] Autor:Muratsu J; Morishima A; Kukida M; Tanaka A; Fujita S; Sakaguchi K
[Ad] Address:Department of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, Japan....
[Ti] Title:The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier.
[So] Source:Case Reports Immunol;2012:929318, 2012.
[Is] ISSN:2090-6609
[Cp] Country of publication:Egypt
[La] Language:eng
[Ab] Abstract:A 42-year-old female who was an asymptomatic carrier of hepatitis B virus (HBV) was diagnosed with antineutrophil cytoplasm antibody- (ANCA-) associated vasculitis and was induced to remission with 30 mg/day prednisolone nine years ago. Four years ago, she suffered recurrence of ANCA-associated vasculitis and with 30 mg/day prednisolone was induced to remission. This time, laboratory data showed 3-fold increase in myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) levels. Administration of 30 mg/day prednisolone was started. Three days later, she was admitted to our hospital suffering from fatigue. After admission, urinalysis showed glomerular hematuria. Despite administration of 30 mg/day prednisolone, MPO-ANCA titer had been of high level, ranging from 42 to 83 EU for 2.5 months. Furthermore, the adverse effects of steroid were seen. We decided the tapering of prednisolone (25 mg/day) and the start of mizoribine (4-carbamoyl-1-ß-D-ribofuranosyl imidazolium-5-olate) administration. After mizoribine treatment, MPO-ANCA titer was decreased without any mizoribine-related adverse effects. Six months later, MPO-ANCA titer was decreased to normal levels and she was induced to clinical remission without reactivation of HBV. We describe the effectiveness of mizoribine for the ANCA-associated vasculitis complicated with HBV-carrier.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1411
[Da] Date of entry for processing:141106
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.1155/2012/929318

  10 / 32464 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 25374732
[Au] Autor:Geake JB; Maguire G
[Ad] Address:Department of Respiratory and Sleep Medicine, Monash Medical Centre, Melbourne, VIC 3206, Australia.
[Ti] Title:Acute spontaneously resolving pulmonary vasculitis: a case report.
[So] Source:Case Reports Immunol;2012:706838, 2012.
[Is] ISSN:2090-6609
[Cp] Country of publication:Egypt
[La] Language:eng
[Ab] Abstract:This is the first description that we are aware of describing the spontaneous resolution of an acute pulmonary vasculitis, possibly secondary to microscopic polyangiitis. Haemoptysis is a common symptom for patients presenting to primary and tertiary referral centres, and pulmonary vasculitis is one of a variety of aetiologies that should always be considered. The pulmonary vasculitides are difficult diagnostic and management problems. They are encumbered by a relative paucity of level 1 evidence addressing their diagnosis, classification, and treatment. This is therefore an important paper to publish because it adds to the global breadth of experience with this important clinical condition.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1411
[Da] Date of entry for processing:141106
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.1155/2012/706838


page 1 of 3247 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information